Sigma-Aldrich

Universities and research institutes are making CRISPR/Cas9 more accessible than ever through new and existing core facilities.

Sales for the firm's life science segment jumped 25 percent year over year to €3.36 billion from €2.68 billion.

After falling for three years in a row, mergers and acquisitions in the omics space rose sharply in 2015, driven by a few billion-dollar-plus deals.

The deal creates a science sector giant able to "cover every step of the biotech production chain."

The firm expects its acquisition by Merck KGaA to be completed this month.

Based on Olink's proximity ligation technology, Duolink allows for detection of low-abundance proteins with higher specificity than conventional immunoassays.

Sigma-Aldrich will participate in the university's Catalyst Program, which is designed to support translation of early biomedical discoveries into commercial products.

Sigma-Aldrich is selling the business in order to gain approval from the EC for its $17 billion acquisition by Merck KGaA announced a year ago. 

The arrayed lentiviral CRISPR/Cas9 guide RNA libraries provide the tools to knock out every known human or mouse protein-coding gene.

Sigma-Aldrich will distribute IROA's Mass Spectrometry Metabolite Library of Standards worldwide. 

Pages

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.